home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  Pharmacogenomics & Personalised Medicine  
  May 11, 2001

Biotechnology

 
     
  SMi conferences, The Hatton, Hatton Gardens, London
25th to 27th September 2001


Day One – Wednesday 26th September

8.30 Registration & Coffee

9.00 Chairman's Opening Remarks
Dr Francois Thomas, VP Pharmacogenomics & Medical Affairs, Genset

INTRODUCTION

9.10 PHARMACOGENETICS: OPPORTUNITIES AND CHALLENGES
 Pharmacogenetics vs pharmacogenomics
 Molecular underpinnings of pharmacogenetics
 Adapting medicines to genetic make-up
 The challenge of clinical research in genetic epidemiology and pharmacogenetics
 Dialogue with the public and finding societal consensus: critical issues
 Future trends and ambitions for the industry
Prof Klaus Lindpaintner, Roche Genetics, F. Hoffmann - La Roche

GENOMICS

SPLICE VARIANTS AS A SOURCE OF PHARMACOGENOMICS MARKERS
9.40 Identifying clinically relevant efficacy and toxicity markers
 Expression profiling strategies
 Proof-Hit: A product in cancer pharmacogenomics
 Expression profiles and SNPs
 Profile-Hit: A product to monitor adverse affects
 Technical platforms
Laurent Bracco, Vice President, Research, ExonHit Therapeutics

REVOLUTIONISING MEDICINE – THE POST-GENOMIC ERA
10.20 Clinical genomics
 The impact of clinical genomics on the elucidation of common diseases
 The importance of maintaining high quality data flow in clinical trials
 Challenges of high throughput screening of SNPs
 The benefits of using clinical trials populations for genomic studies
 Linking genomics with medicine: clinical resources for the post-genomic era
 Drug targeting: future approaches
Dr Steven Butcher, Vice President, Science, Gemini Genomics

11.00 Morning Coffee

GENOMICS AND THERAPEUTIC TARGET GENE DISCOVERY
11.20 Developing effective methodologies
 The inverse genomics approach
 The importance of functional genomics in linking disease related genes to functional drugs
 Genetic validation
 Requirements for drug target validation in the post-genomic era
 Target selection strategies in genomics
 Integrating genomic structure and function
Dr Krishnan Nandobalan, Vice President, Product Development, Genaissance Pharmaceuticals

MOLECULAR EVOLUTION
12.00 Case study: Aptagen and Protein GenesisTM
 What is Protein GenesisTM
 Integration with Enzyme EvolutionTM
 Advancing product development
 Incorporation for large-scale drug target validation
 Enhancing the functions of existing proteins and enyzmes
 Creating and testing diversity
Dr Colin Higbie, President, Aptagen

12.40 Networking Lunch

GENOMICS AND MEDICINE
2.00 Maximising information output in functional genomics using zinc finger proteins
 Overview of the applications of genomics
 Application of functional genomics techniques to the discovery and development of pharmaceuticals
 High throughput methodologies for target identification and validation
 Target validation using engineered zinc finger transcription factors
 The future of functional genomics
Dr Yen Choo, Research Director, Gendaq

PHARMACOGENOMICS IN ONCOLOGY
2.40 Applications
 Molecular profiling as a new tool for the determination of cancer classification and prognosis
 Pharmacogenomics in the discovery and development of anticancer drugs
 Defining the role of different genomic technologies
Dr Francois Thomas, Vice President, Pharmacogenomics & Medical Affairs, Genset

3.20 Afternoon Tea

DRUG DISCOVERY

INTEGRATING BIOINFORMATICS TO ACCELERATE DRUG DISCOVERY
3.40 The bioinformatics revolution
 Integration issues in pharmaceutical informatics
 The interface of data analysis technologies
 Linking bioinformatics with proteomics and high throughput screening to improve drug development
 Utilising bioinformatics systems for high throughput data analysis
 The effective use of bioinformatics in drug design
 Bioinformatics & IT: enabling cutting edge drug discovery and design
Dr Christos Hatzis, Co-founder & Vice President, Technology Development, Silico Insights

INTEGRATING SNPS INTO THE DRUG DISCOVERY PROCESS
4.20 Developing genetic-based diagnostics using the SNP database
 Why are SNPs so important?
 The importance of characterising SNPs and haplotypes in target genes
 Target prioritisation: the potential of genetic polymorphisms
 Structural pharmacogenomics: designing new and improved drugs
 SNPs: improving public awareness
 Advancing medicine through SNP maps
Dr Mark Brann, President & Chief Scientific Officer, Acadia Pharmaceuticals

5.00 Chairman’s Closing Remarks and Close of Day One

Day Two – Thursday 27th September 2001

8.30 Re-registration and Coffee

9.00 Chairman's Opening Remarks
Dr Leslie Hudson, Senior Vice President, Global Business Management, Head, Emerging Technologies, Pharmacia

COMMERCIAL ISSUES

THE BUSINESS OF GENOMICS
9.10 Personalised drugs?
 Applications of pharmacogenomics
 Pharmacogenetics – bridging the gap between gene discovery and drug development
 A new way for personalised medicine – to genotype or not to genotype?
 Targeted healthcare models
 Ethical, legal and social implications
 To know or not to know?
Dr Mihael Polymeropoulos, Pharmacogenomics, Novartis

IMPACT OF PHARMACOGENOMICS ON THE PHARMACEUTICAL MARKET
9.40 The industry perspective
 Initiating an effective pharmacogenomics strategy
 The direct impact on pharmaceutical R & D: target identification to validation
 Shaping the way pharmaceuticals are commercialised
 Improving decision making in R & D
 Market positioning
 Projecting the market for the future
Dr Matthew Kalnik, Executive Director, Global Prescription Business, Emerging Technologies, & Head, Pharmacogenomics, Pharmacia

INVESTING FOR THE FUTURE
10.20 New opportunities for pharmacogenomics
 Building the novel venture to create real value
 Delivering on the promise of pharmacogenomics
 Realising the opportunities
 Avoiding intellectual property pitfalls
 Creating the right business model
 Evaluating pharmacogenomics for the future
Dr Gregory Brown, Managing Director, Head, Healthcare, Adams, Harkness & Hill

11.00 Morning coffee

INTELLECTUAL PROPERTY ISSUES IN PHARMACOGENOMICS
11.20 Genetic patenting
 Current issues in genetic patenting
 Genetic polymorphisms
 SNPs…
 Making the most of your IP
 R&D and licensing agreements
 Biotech patent litigation: current infringement and validity issues
Sarah Turner, Lawyer, Lovells

DRUG DISCOVERY TECHNOLOGY
12.00 Realising the potential of pharmacogenomics
 Impact of pharmacogenomics on the drug discovery process
 Technology for high-throughput drug discovery from “genomics targets”
 The key role of informatics
 Potential for improving the odds for successful drug development & clinical trials
 Successful partnership strategies
Dr Raymond Salemme, President & Chief Scientific Officer, 3D Pharmaceuticals

12.40 Networking Lunch

THE SCIENCE AND BUSINESS OF PHARMACOGENOMICS
2.00 Implications for the genomics revolution
 Application of pharmacogenomics
 SNP mapping – its potentials and challenges
 DNA probe arrays for pharmacogenomic discovery
 The challenges of data management and utility
 Future for pharmacogenomics
Dr Mark Egerton, Vice President, Incyte Pharmaceuticals

FROM “ONE DRUG FITS ALL” TO PERSONALISED THERAPY
2.40 The implications of pharmacogenetics and pharmacogenomics at the individual and population level
 Adverse drug reactions and post marketing drug safety: is pharmacogenetics the answer?
 Focusing on drug response
 The role of pharmacogenetics, pharmacogenomics and pharmacoepidemiology in drug surveillance and effectiveness: the individual and population approaches
 Enhancing the value of current drugs
 Challenging the “one drug fits all” approach
 Limitations for pharmacogenetics and pharmacogenomics
Dr Joan Soriano, Principal Epidemiologist, GlaxoSmithKline

3.20 Afternoon Tea

FROM CORPORATE STRATEGY TO ALLIANCE STRATEGY
3.40 How can alliances contribute to success
 Linking alliances to corporate strategy
 Developing strategic vision
 Setting and achieving expectations for partnerships
 Assessing and developing winning relationships
Anton Gueth, Director, Alliance Management, Eli Lilly

COMMERCIAL IMPLICATIONS OF PHARMACOGENETICS
4.20 Navigating the future healthcare marketplace
 What are the bottlenecks in getting to market?
 Pharmacogenetics: altering the face of pharmaceutical marketing
 Improving intervention at earlier stages
 Implementation of new clinical regimens
 Novel routes for commercialisation
 Barriers to adopting pharmacogenetics
Dr Michael Luther, Head, Strategy, Business & Product Development, Pharmacogenetics & Applied Diagnostics, GlaxoSmithKline

5.00 Chairman’s Closing Remarks and Close of Day Two


Image is Everything: Public Relations & Public Perception of Biotech
25th September 2001,The Hatton, London
[In association with: Aptagen]
 
 
Organized by: Louise Maher
Invited Speakers: A unique opportunity to learn from leading industry experts including:
 Prof Klaus Lindpaintner, Roche Genetics, F. Hoffmann - La Roche
 Dr Joan Soriano, Principal Epidemiologist, GlaxoSmithKline
 Dr Mihael Polymeropoulos, Pharmacogenomics, Novartis
 Dr Michael Luther, Head, Strategy, Business & Product Development, Pharmacogenetics & Applied Diagnostics, GlaxoSmithKline
 Anton Gueth, Director, Alliance Management, Eli Lilly
 Dr Matthew Kalnik, Executive Director, Global Prescription Business, Emerging Technologies, & Head, Pharmacogenomics, Pharmacia
 Dr Francois Thomas, Vice President, Pharmacogenomics & Medical Affairs, Genset
 Dr Steven Butcher, Vice President, Science, Gemini Genomics
 Dr Krishnan Nandabalan, Vice President, Product Development, Genaissance Pharmaceuticals
 Dr Mark Egerton, Vice President, Incyte Pharmaceuticals
 Dr Mark Brann, President & Chief Scientific Officer, Acadia Pharmaceuticals
 Dr Raymond Salemme, President & Chief Scientific Officer, 3D Pharmaceuticals
 Dr Yen Choo, Research Director, Gendaq
 Dr Colin Higbie, President, Aptagen
 Dr Laurent Bracco, Vice President, Research, ExonHit Therapeutics
 Dr Christos Hatzis, Co-founder & Vice President, Technology Development, Silico Insights
 Dr Gregory Brown, Managing Director, Head, Healthcare, Adams, Harkness & Hill
 Sarah Turner, Lawyer, Lovells

Chaired by:
 Dr Leslie Hudson, Senior Vice President, Global Business Management, Head, Emerging Technologies, Pharmacia
 Dr Francois Thomas, Vice President, Pharmacogenomics & Medical Affairs, Genset
 
Deadline for Abstracts: No abstracts required
 
Registration: £1099 + VAT
E-mail: customer_services@smi-online.co.uk
 
  Posted by:   Louise Maher  
Host: 213.38.112.46
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2001 HUM-MOLGEN. All rights reserved. Liability and Copyright.